Results 221 to 230 of about 98,807 (272)

Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results. [PDF]

Clin Cancer Res
Rosen EY, Yap TA, Fontana E, Lee EK, Mahalingam D, Højgaard M, Mettu NB, Cote GM, Plummer R, Koehler M, Ulanet D, Fei K, Silverman IM, Schonhoft JD, Rimkunas V, Bacque ES, Gomez G, Fretland AJ, Roulston A, Li L, Baruah P, Zimmermann M, Yang J, Carneiro BA, Lheureux S.   +24 more
europepmc   +1 more source

The Differential Impact of Neoadjuvant Therapies on the Tumor Microenvironment, Peripheral Biomarkers, and Survival in Pancreatic Cancer: A Retrospective Cohort Study. [PDF]

Cancers (Basel)
Silva T, Yamazaki T, Creasy JM, Gerry JM, Zheng-Lin B, Srivastava AJ, Young KH.   +6 more
europepmc   +1 more source

Efficacy and Toxicity in Scheduled Intravesical Gemcitabine Versus Bacillus Calmette-Guérin for Bladder Cancer: A Systematic Review and Meta-Analysis. [PDF]

Cancers (Basel)
Kim DK, Jeon J, Kwon JK, Bang S, Lee KS, Koo KC, Cho KS.   +6 more
europepmc   +1 more source

Evodiamine Inactivates NF-κB and Potentiates the Antitumor Effects of Gemcitabine on Tongue Cancer Both in vitro and in vivo [Retraction]. [PDF]

Onco Targets Ther
europepmc   +1 more source